A067630 Stock Overview
HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HLB Life Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,310.00 |
| 52 Week High | ₩25,000.00 |
| 52 Week Low | ₩8,260.00 |
| Beta | 0.44 |
| 1 Month Change | -13.15% |
| 3 Month Change | 64.08% |
| 1 Year Change | 64.08% |
| 3 Year Change | 51.08% |
| 5 Year Change | 119.34% |
| Change since IPO | 904.41% |
Recent News & Updates
Recent updates
HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up
Mar 15
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
Feb 14Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings
Dec 06Shareholder Returns
| A067630 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | 3.1% | -1.1% | -3.3% |
| 1Y | 64.1% | 15.3% | 1.2% |
Return vs Industry: A067630 exceeded the KR Healthcare industry which returned 15.3% over the past year.
Return vs Market: A067630 exceeded the KR Market which returned 1.2% over the past year.
Price Volatility
| A067630 volatility | |
|---|---|
| A067630 Average Weekly Movement | 13.6% |
| Healthcare Industry Average Movement | 5.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A067630's share price has been volatile over the past 3 months.
Volatility Over Time: A067630's weekly volatility has increased from 8% to 14% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 110 | Sung-Bo Sim | www.hlb-ls.com |
HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the company is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses, as well as manufactures and sells disposable syringes.
HLB Life Science Co., Ltd. Fundamentals Summary
| A067630 fundamental statistics | |
|---|---|
| Market cap | ₩1.86t |
| Earnings (TTM) | -₩5.98b |
| Revenue (TTM) | ₩97.99b |
19.0x
P/S Ratio-311.2x
P/E RatioIs A067630 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A067630 income statement (TTM) | |
|---|---|
| Revenue | ₩97.99b |
| Cost of Revenue | ₩98.92b |
| Gross Profit | -₩925.04m |
| Other Expenses | ₩5.06b |
| Earnings | -₩5.98b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -55.62 |
| Gross Margin | -0.94% |
| Net Profit Margin | -6.11% |
| Debt/Equity Ratio | 71.5% |
How did A067630 perform over the long term?
See historical performance and comparison